Safety of PCI-32765 in Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the safety and efficacy of orally administered
PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.